- The study, conducted in collaboration with the Department of
Biomedicine and Prevention at the University of Rome Tor
Vergata and Tor Vergata University Hospital, underscores
the relevance of polygenic risk scores (PRS) in risk stratification
for patients with a genetic predisposition to breast
cancer.
MADRID, Oct. 3, 2024
/CNW/ -- Veritas Genetics, in collaboration with the Department of
Biomedicine and Prevention at the University of Rome Tor Vergata
and the Tor Vergata University Hospital, has published the results
of an innovative pilot study demonstrating the importance of
polygenic risk scores (PRS) in identifying and managing women with
a high risk of developing breast cancer.
This groundbreaking study, led by Professor Giuseppe Novelli from the University of
Tor Vergata in collaboration with
key members of Veritas' medical-scientific team (Dr. Vincenzo Cirigliano, Dr. Luis Izquierdo, Giuliana
Longo, and Bibiana Palao),
suggests that PRS, combined with the assessment of known pathogenic
variants, can provide a more accurate risk evaluation for both
carriers and non-carriers of mutations in genes such as
BRCA1, BRCA2, PALB2, and ATM.
Key Findings of the Study
The study, published in the Journal of Personalized Medicine,
evaluated women with a family history of breast cancer,
demonstrating that PRS significantly improves the accuracy of
individual risk prediction. This is particularly relevant for women
who are non-carriers of pathogenic variants in susceptibility
genes. For carriers of mutations in genes like BRCA1 and
BRCA2, PRS offers a complementary approach that helps refine
personalized management and prevention strategies.
According to Dr. Izquierdo, Chief Medical Officer at Veritas,
"This study reaffirms the clinical value of genomic tools in
personalizing preventive medicine. The use of PRS, along with
traditional genetic evaluation, allows healthcare professionals to
offer more precise and tailored care to the individual needs of
each patient, ultimately improving long-term outcomes."
An Essential Tool for Personalized Medicine
PRS has the potential to transform how cancer risk is assessed
and managed in patients with a family history of the disease. Dr.
Izquierdo, added: "Polygenic risk scoring not only provides a
deeper evaluation of genetic risk but also redefines how we
understand cancer susceptibility in families with a history of the
disease. This tool is key to the future of personalized medicine
and the proactive management of complex conditions like breast
cancer."
About Veritas Genetics
Veritas Genetic leads the implementation of advanced genomic
solutions, focusing on preventive and personalized medicine.
Through partnerships with top-tier academic institutions, Veritas
continues to drive innovation aimed at improving health and
well-being.
www.veritasint.com
https://www.mdpi.com/2975338
View original
content:https://www.prnewswire.com/news-releases/veritas-genetic-participates-in-a-groundbreaking-study-highlighting-the-importance-of-polygenic-risk-scores-in-the-clinical-management-of-breast-cancer-patients-302265815.html
SOURCE Veritas Genetics